Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22524348 | 0.84 | CCNB2 (0.45) | CCNB2CDK1CCNB1CCNB3TLR8 | |
| SCHEMBL22524353 | 0.80 | CCNB2 (0.42) | CCNB2CDK1CCNB1CCNB3TLR8 | |
| SCHEMBL22524323 | 0.79 | CCNB2 (0.41) | CCNB2CDK1CCNB1CCNB3TLR8 | |
| SCHEMBL22224125 | 0.78 | CYP3A4 (0.50) | TLR8TLR7SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22524343 | 0.77 | CCNB2 (0.43) | CCNB2CDK1CCNB1CCNB3TLR8 | |
| SCHEMBL22524344 | 0.77 | CCNB2 (0.40) | CCNB2CDK1CCNB1CCNB3TLR8 | |
| SCHEMBL22524250 | 0.77 | CCNB2 (0.40) | CCNB2CDK1CCNB1CCNB3TLR8 | |
| SCHEMBL20420131 | 0.75 | YTHDC1 (0.49) | LMNAALDH1A1 | |
| SCHEMBL796516 | 0.75 | HTT (0.49) | CCNB2CDK1CCNB1CCNB3TLR8 | |
| SCHEMBL22524205 | 0.73 | SMN1; SMN2 (0.47) | CCNB2CDK1CCNB1CCNB3TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2020206363-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ,INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, PINK1, NME4 | CCNB2 4201/4885CDK1 1441/4885CCNB1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.